Interferon-α and-Β in kidney inflammation

Kidney International

Volumn 77, Issue 10, 2010, Pages 848-854

  Anders, Hans Joachim ^a   Lichtnekert, Julia ^a   Allam, Ramanjaneyulu ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Inflammation; Innate immunity; Interferon; Toll like receptor; Viral infection

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

ACUTE KIDNEY FAILURE; GENE; GLOMERULONEPHRITIS; HUMAN; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SHORT SURVEY; VIRUS INFECTION; VIRUS NEPHROPATHY;

EID: 77951856955     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.71     Document Type: Short Survey

References (54)

1. Borden EC, Sen GC, Uze G et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6: 975-990.
2. Berns JS, Bloom RD. Viral nephropathies: core curriculum 2008. Am J Kidney Dis 2008; 52: 370-381.
3. Waldman M, Marshall V, Whitby D et al. Viruses and kidney disease: beyond HIV. Semin Nephrol 2008; 28: 595-607.
4. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005; 5: 375-386.
5. Biron CA. Interferons alpha and beta as immune regulators\a new look. Immunity 2001; 14: 661-664.
6. Theofilopoulos AN, Baccala R, Beutler B et al. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-336.
7. Taniguchi T, Ogasawara K, Takaoka A et al. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 623-655.
8. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006; 312: 879-882.
9. Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015.
10. Alexopoulou L, Holt AC, Medzhitov R et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
11. Diebold SS, Kaisho T, Hemmi H et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531.
12. Heil F, Hemmi H, Hochrein H et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303: 1526-1529.
13. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745.
14. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227: 75-86.
15. Barbalat R, Lau L, Locksley RM et al. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009; 10: 1200-1207.
16. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009; 138: 576-591.
17. Takaoka A, Wang Z, Choi MK et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501-505.
18. Genin P, Vaccaro A, Civas A. The role of differential expression of human interferon\a genes in antiviral immunity. Cytokine Growth Factor Rev 2009; 20: 283-295.
19. Kumagai Y, Kumar H, Koyama S et al. Cutting edge: TLR-dependent viral recognition along with type I IFN positive feedback signaling masks the requirement of viral replication for IFN-{alpha} production in plasmacytoid dendritic cells. J Immunol 2009; 182: 3960-3964.
20. Anders HJ. Innate pathogen recognition in the kidney: Toll-like receptors, NOD-like receptors, and RIG-like helicases. Kidney Int 2007; 72: 1051-1056.
21. Flur K, Allam R, Zecher D et al. Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5: implications for viral infection-associated glomerulonephritis. Am J Pathol 2009; 175: 2014-2022.
22. Hagele H, Allam R, Pawar RD et al. Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. Nephrol Dial Transplant 2009; 24: 3312-3318.
23. Allam R, Lichtnekert J, Moll A et al. Viral RNA and DNA sense common antiviral responses including type I interferons in mesangial cells. J Am Soc Nephrol 2009; 20: 1986-1996.
24. Hagele H, Allam R, Pawar RD et al. Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway. Am J Pathol 2009; 175: 1896-1904.
25. Patole PS, Pawar RD, Lech M et al. Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol Dial Transplant 2006; 21: 3062-3073.
26. Kimmel PL, Cohen DJ, Abraham AA et al. Upregulation of MHC class II, interferon-alpha and interferon-gamma receptor protein expression in HIV-associated nephropathy. Nephrol Dial Transplant 2003; 18: 285-292.
27. Strauss J, Abitbol C, Zilleruelo G et al. Renal disease in children with the acquired immunodeficiency syndrome. N Engl J Med 1989; 321: 625-630.
28. Munz C, Lunemann JD, Getts MT et al. Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol 2009; 9: 246-258.
29. Pawar RD, Patole PS, Zecher D et al. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 2006; 17: 141-149.
30. Fairhurst AM, Mathian A, Connolly JE et al. Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. Eur J Immunol 2008; 38: 1948-1960.
31. Schwarting A, Paul K, Tschirner S et al. Interferon-beta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005; 16: 3264-3272.
32. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-2142.
33. Agrawal H, Jacob N, Carreras E et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009; 183: 6021-6029.
34. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15-25.
35. Santiago-Raber ML, Baccala R, Haraldsson KM et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
36. Nacionales DC, Kelly-Scumpia KM, Lee PY et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007; 56: 3770-3783.
37. Lu Q, Shen N, Li XM et al. Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice. Genes Immun 2007; 8: 590-603.
38. Kyogoku C, Tsuchiya N. A compass that points to lupus: genetic studies on type I interferon pathway. Genes Immun 2007; 8: 445-455.
39. Ronnblom L, Alm GV, Eloranta ML. Type I interferon and lupus. Curr Opin Rheumatol 2009; 21: 471-477.
40. Yang AH, Lin BS, Kuo KL et al. The clinicopathological implications of endothelial tubuloreticular inclusions found in glomeruli having histopathology of idiopathic membranous nephropathy. Nephrol Dial Transplant 2009; 24: 3419-3425.
41. Marshak-Rothstein A, Rifkin IR. Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 2007; 25: 419-441.
42. Anders HJ. Pseudoviral immunity\a novel concept for lupus. Trends Mol Med 2009; 15: 553-561.
43. Dong L, Ito S, Ishii KJ et al. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum 2005; 52: 651-658.
44. Lenert P, Yasuda K, Busconi L et al. DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Faslpr/lpr mice in vivo. Arthritis Res Ther 2009; 11: R79.
45. Patole PS, Zecher D, Pawar RD et al. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005; 16: 3273-3280.
46. Barrat FJ, Meeker T, Chan JH et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37: 3582-3586.
47. Pawar RD, Ramanjaneyulu A, Kulkarni OP et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007; 18: 1721-1731.
48. Yao Y, Richman L, Higgs BW et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1785-1796.
49. Fairhurst AM, Xie C, Fu Y et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 2009; 183: 6831-6838.
50. Lichtnekert J, Vielhauer V, Zecher D et al. Trif is not required for immune complex glomerulonephritis: dying cells activate mesangial cells via Tlr2/Myd88 rather than Tlr3/Trif. Am J Physiol Renal Physiol 2009; 296: F867-F874.
51. Satchell SC, Buchatska O, Khan SB et al. Interferon-beta reduces proteinuria in experimental glomerulonephritis. J Am Soc Nephrol 2007; 18: 2875-2884.
52. Anders HJ, Vielhauer V, Eis V et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004; 18: 524-526.
53. Allam R, Pawar RD, Kulkarni O et al. Viral 5-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol 2008; 38: 3487-3498.
54. Freitas MCS et al. Type I IFN pathway mediates kidney ischemia-reperfusion injury. ASN Renal Week 2009, abstract F-FC210.